Showing results (161-170 of 220) with videos related to

Sort By:
Pageof 22
European Heart Journal|May 23, 1998
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromesE Braunwald, A Maseri, P W Armstrong, et al.
Journal of General Microbiology|October 1, 1986
Bacteriophages F0lac h, SR, SF: phages which adsorb to pili encoded by plasmids of the S-complexJ N Coetzee, D E Bradley, R W Hedges, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 15, 1995
Maximizing the benefits of thrombolytic therapy for acute myocardial infarctionJ Cairns, P W Armstrong, I Belenkie, et al.
Circulation|September 20, 2000
Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II InvestigatorsY Fu, W C Chang, D Mark, et al.
American Heart Journal|April 16, 1998
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromesE Braunwald, A Maseri, P W Armstrong, et al.
European Heart Journal|February 8, 2003
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-makingL K Newby, V Hasselblad, P W Armstrong, et al.
European Journal of Heart Failure|December 13, 2000
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study GroupM J Sculpher, L Poole, J Cleland, et al.
The American Journal of Cardiology|August 15, 1993
Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study GroupA Haq, C D Morgan, R F Wilson, et al.
Circulation|December 11, 1999
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study GroupM Packer, P A Poole-Wilson, P W Armstrong, et al.
Heart (British Cardiac Society)|March 19, 2005
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trialR C Welsh, W Chang, P Goldstein, et al.
Pageof 22